A Biopharmaceutical Firm Finds Out Antibodies Capable Of Killing Multiple Strains Of COVID19 Virus

A Biopharmaceutical Firm Finds Out Antibodies Capable Of Killing Multiple Strains Of COVID19 Virus

February 26, 2021 Off By Emma Taylor

A firm called Immunome Inc. that designs and discovers antibody therapies using its human memory B cells platform has found some potent antibodies, which can kill many variants of the SARS-CoV-2 virus. Scientists from the firm have said that these antibodies can eliminate the variant of the virus, which has been found in South Africa. The South African strain of the virus is known as B.1.351. The efficacy of these antibodies has been proven in pseudovirus testing. This study is a part of the company’s program to come up with a mix of antibodies to target spike or non-spike proteins, which can act as prophylaxis or a cure for COVID19. The COVID19 antibody research program of the firm shows that super responders of the virus who have recovered from the disease build up a robust immune response to a wide range of viral targets. Experts have said that they have found these antibodies, which have the ability to bind to non-flapping areas of the spike protein along with those areas that have the mutational strains while making the antibody mix. The study has noted that some antibodies can kill pseudoviruses, which express the spike protein of the South African variant. Past studies have shown that the strain, which has been found in South Africa, is able to dodge vaccines and antibody treatments.

The officials of the firm have said that Immunome’s discovery engine has been able to find antibodies that can bind to sealed epitopes of SARS-CoV-1 and SARS-CoV-2 spike. These antibodies have the potential to bind to other non-spike targets as well. They have claimed that their inclusive approach might be able to fight the negative effect of escape mutants. The findings of the study have been quite encouraging, said the experts. They are going to continue their efforts to come up with a viable treatment with these antibodies. Jeffrey P. Henderson from Washington of University has said that testing the overall immune retorts in patients who have recovered from COVID19 allows finding out not only anti-spike antibodies but potent non-spike antibodies as well, which can shoot up the potential viral clearance. He has said that largely aiming at multiple viral proteins in this way will offer other means to fight against other strains of the SARS-CoV-2 in the future.

Last year, the company has been presented with a $13.3 million technology award by JPEO-CBRND, the US Department of Defense’s Joint Program Executive Office for Chemical Biological, Radiological, and Nuclear Defense. This award has been given to the firm in association with the Defense Health Agency. The objective of this award has been to support the company’s COVID19 program. If the findings of this research are confirmed, experts will be able to come up with an effective treatment for the disease.